Details for Patent: 10,596,107

Which drugs does patent 10,596,107 protect, and when does it expire?

Patent 10,596,107 protects LOTEMAX SM and is included in one NDA.

This patent has thirty patent family members in thirteen countries.

Summary for Patent: 10,596,107

Patent landscape, scope, and claims:

Title:	Ophthalmic suspension composition
Abstract:	A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 .mu.m and D.sub.v50<1 .mu.m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
Inventor(s):	Shawer; Mohannad (Lexington, MA), Phillips; Eric (Ontario, NY), Coffey; Martin J. (Buffalo Grove, IL)
Assignee:	Bausch & Lomb Incorporated (Rochester, NY)
Application Number:	15/006,525
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,596,107
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,596,107

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	LOTEMAX SM	loteprednol etabonate	GEL;OPHTHALMIC	208219-001	Feb 22, 2019		RX	Yes	Yes			Y			TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY

International Family Members for US Patent 10,596,107

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016211745
Australia	2021203027
Australia	2023248145
Brazil	112017016016